Stanmore appoints Eric Dodd CFO
This article was originally published in Clinica
Executive Summary
UK orthopaedics firm Stanmore Implants has appointed Eric Dodd chief financial officer. Mr Dodd was most recently CFO of European biotech company Antisoma, a position he held for three years. Before this, he was group finance director for Morse, a British IT consultancy group. Mr Dodd has also worked for GlaxoSmithKline and Deloitte & Touche. Elstree-based Stanmore is currently expanding its product offering and entering new markets. In June, the company received US FDA 510(k) clearance for its Juvenile Tumour System (JTS), a noninvasive distal femoral replacement implant that uses an electromagnetic device to lengthen the prosthesis (www.clinica.co.uk, 27 June 2011).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.